Citadel Advisors
AVNR

Citadel Advisors’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Citadel Advisors’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-27,100
Closed -$459K – 9291
2014
Q4 		$459K Sell
27,100
-26,500
-49% -$373K ﹤0.01% 4835
2014
Q3 		$639K Buy
53,600
+38,400
+253% +$262K ﹤0.01% 4311
2014
Q2 		$86K Sell
15,200
-12,400
-45% -$57.1K ﹤0.01% 6354
2014
Q1 		$101K Buy
27,600
+7,800
+39% +$29.7K ﹤0.01% 6195
2013
Q4 		$67K Sell
19,800
-20,600
-51% -$85.1K ﹤0.01% 5885
2013
Q3 		$171K Buy
40,400
+15,900
+65% +$75.3K ﹤0.01% 4914
2013
Q2 		$113K Buy
+24,500
New +$84.2K ﹤0.01% 5131

Citadel Advisors's AVNR Position: Q4 2014 in Review

Citadel Advisors sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 1,691,547 shares — an estimated $23.8M sold.

Citadel Advisors first reported a position in AVNR in Q2 2013 and held it in 6 quarters. The position peaked at $20.2M in Q3 2014. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

  • Citadel Advisors reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
  • Citadel Advisors sold 1,691,547 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $23.8M.
  • Citadel Advisors first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 6 quarters.
  • Citadel Advisors's AVANIR PHARMACEUTICALS, INC CL A position peaked at $20.2M in Q3 2014.
  • 166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on Citadel Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.